Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus.

@article{Lamendola2013EffectOR,
  title={Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus.},
  author={Priscilla Lamendola and Roberto Nerla and Dario Pitocco and Angelo Villano and Giuseppe Scavone and Alessandra Stazi and Giulio Russo and Antonino Di Franco and Alfonso Sestito and Giovanni Ghirlanda and Gaetano Antonio Lanza and Filippo Crea},
  journal={Atherosclerosis},
  year={2013},
  volume={226 1},
  pages={157-60}
}
OBJECTIVE To assess the effect of ranolazine on systemic vascular function in patients with type II diabetes mellitus (T2DM). METHODS We randomized 30 consecutive T2DM patients with no evidence of cardiovascular disease and no insulin therapy to receive one of the following 3 forms of treatment in a blinded fashion: ranolazine, 375 mg bid for 3 weeks (group 1); ranolazine, 375 mg bid for 2 weeks, followed by placebo bid for 1 week (group 2); placebo bid for 3 weeks (group 3). Flow-mediated… CONTINUE READING